Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Resistance to MAPK Inhibitors in Melanoma Involves Activation of the IGF1R-MEK5-Erk5 Pathway.

Benito-Jardón L, Díaz-Martínez M, Arellano-Sánchez N, Vaquero-Morales P, Esparís-Ogando A, Teixidó J.

Cancer Res. 2019 May 1;79(9):2244-2256. doi: 10.1158/0008-5472.CAN-18-2762. Epub 2019 Mar 4.

PMID:
30833419
2.

MEK5 promotes lung adenocarcinoma.

Sánchez-Fdez A, Ortiz-Ruiz MJ, Re-Louhau MF, Ramos I, Blanco-Múñez Ó, Ludeña D, Abad M, Sánchez-Martín M, Pandiella A, Esparís-Ogando A.

Eur Respir J. 2019 Feb 28;53(2). pii: 1801327. doi: 10.1183/13993003.01327-2018. Print 2019 Feb. No abstract available.

3.

ODZ1 allows glioblastoma to sustain invasiveness through a Myc-dependent transcriptional upregulation of RhoA.

Talamillo A, Grande L, Ruiz-Ontañon P, Velasquez C, Mollinedo P, Torices S, Sanchez-Gomez P, Aznar A, Esparis-Ogando A, Lopez-Lopez C, Lafita C, Berciano MT, Montero JA, Vazquez-Barquero A, Segura V, Villagra NT, Pandiella A, Lafarga M, Leon J, Martinez-Climent JA, Sanz-Moreno V, Fernandez-Luna JL.

Oncogene. 2017 Mar 23;36(12):1733-1744. doi: 10.1038/onc.2016.341. Epub 2016 Sep 19.

PMID:
27641332
4.

Targeting the EGF/HER Ligand-Receptor System in Cancer.

Esparís-Ogando A, Montero JC, Arribas J, Ocaña A, Pandiella A.

Curr Pharm Des. 2016;22(39):5887-5898. Review.

PMID:
27426127
5.

Neuregulin expression in solid tumors: prognostic value and predictive role to anti-HER3 therapies.

Ocaña A, Díez-González L, Esparís-Ogando A, Montero JC, Amir E, Pandiella A.

Oncotarget. 2016 Jul 19;7(29):45042-45051. doi: 10.18632/oncotarget.8648.

6.

Therapeutic potential of ERK5 targeting in triple negative breast cancer.

Ortiz-Ruiz MJ, Álvarez-Fernández S, Parrott T, Zaknoen S, Burrows FJ, Ocaña A, Pandiella A, Esparís-Ogando A.

Oncotarget. 2014 Nov 30;5(22):11308-18.

7.

The mitogen-activated protein kinase ERK5 regulates the development and growth of hepatocellular carcinoma.

Rovida E, Di Maira G, Tusa I, Cannito S, Paternostro C, Navari N, Vivoli E, Deng X, Gray NS, Esparís-Ogando A, David E, Pandiella A, Dello Sbarba P, Parola M, Marra F.

Gut. 2015 Sep;64(9):1454-65. doi: 10.1136/gutjnl-2014-306761. Epub 2014 Sep 2.

8.

ERK5/BMK1 is a novel target of the tumor suppressor VHL: implication in clear cell renal carcinoma.

Arias-González L, Moreno-Gimeno I, del Campo AR, Serrano-Oviedo L, Valero ML, Esparís-Ogando A, de la Cruz-Morcillo MÁ, Melgar-Rojas P, García-Cano J, Cimas FJ, Hidalgo MJ, Prado A, Callejas-Valera JL, Nam-Cha SH, Giménez-Bachs JM, Salinas-Sánchez AS, Pandiella A, del Peso L, Sánchez-Prieto R.

Neoplasia. 2013 Jun;15(6):649-59.

9.

Potent antimyeloma activity of a novel ERK5/CDK inhibitor.

Álvarez-Fernández S, Ortiz-Ruiz MJ, Parrott T, Zaknoen S, Ocio EM, San Miguel J, Burrows FJ, Esparís-Ogando A, Pandiella A.

Clin Cancer Res. 2013 May 15;19(10):2677-87. doi: 10.1158/1078-0432.CCR-12-2118. Epub 2013 Mar 26.

10.

Cellular plasticity confers migratory and invasive advantages to a population of glioblastoma-initiating cells that infiltrate peritumoral tissue.

Ruiz-Ontañon P, Orgaz JL, Aldaz B, Elosegui-Artola A, Martino J, Berciano MT, Montero JA, Grande L, Nogueira L, Diaz-Moralli S, Esparís-Ogando A, Vazquez-Barquero A, Lafarga M, Pandiella A, Cascante M, Segura V, Martinez-Climent JA, Sanz-Moreno V, Fernandez-Luna JL.

Stem Cells. 2013 Jun;31(6):1075-85. doi: 10.1002/stem.1349.

11.

Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer.

Montero JC, Esparís-Ogando A, Re-Louhau MF, Seoane S, Abad M, Calero R, Ocaña A, Pandiella A.

Oncogene. 2014 Jan 9;33(2):148-56. doi: 10.1038/onc.2012.572. Epub 2012 Dec 17.

PMID:
23246963
12.

ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy.

Aceves-Luquero CI, Agarwal A, Callejas-Valera JL, Arias-González L, Esparís-Ogando A, del Peso Ovalle L, Bellón-Echeverria I, de la Cruz-Morcillo MA, Galán Moya EM, Moreno Gimeno I, Gómez JC, Deininger MW, Pandiella A, Sánchez Prieto R.

PLoS One. 2009 Jul 1;4(7):e6124. doi: 10.1371/journal.pone.0006124.

13.

Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as a potential therapeutic target.

Montero JC, Ocaña A, Abad M, Ortiz-Ruiz MJ, Pandiella A, Esparís-Ogando A.

PLoS One. 2009;4(5):e5565. doi: 10.1371/journal.pone.0005565. Epub 2009 May 15.

14.

Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells.

Esparís-Ogando A, Ocaña A, Rodríguez-Barrueco R, Ferreira L, Borges J, Pandiella A.

Ann Oncol. 2008 Nov;19(11):1860-9. doi: 10.1093/annonc/mdn406. Epub 2008 Jul 17.

PMID:
18641009
15.

The mitogen-activated protein kinase Erk5 mediates human mesangial cell activation.

Dorado F, Velasco S, Esparís-Ogando A, Pericacho M, Pandiella A, Silva J, López-Novoa JM, Rodríguez-Barbero A.

Nephrol Dial Transplant. 2008 Nov;23(11):3403-11. doi: 10.1093/ndt/gfn333. Epub 2008 Jun 21.

PMID:
18567890
16.

Neuregulins and cancer.

Montero JC, Rodríguez-Barrueco R, Ocaña A, Díaz-Rodríguez E, Esparís-Ogando A, Pandiella A.

Clin Cancer Res. 2008 Jun 1;14(11):3237-41. doi: 10.1158/1078-0432.CCR-07-5133. Review.

17.

Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer.

de Alava E, Ocaña A, Abad M, Montero JC, Esparís-Ogando A, Rodríguez CA, Otero AP, Hernández T, Cruz JJ, Pandiella A.

J Clin Oncol. 2007 Jul 1;25(19):2656-63.

PMID:
17602072
18.

Erk5 nuclear location is independent on dual phosphorylation, and favours resistance to TRAIL-induced apoptosis.

Borges J, Pandiella A, Esparís-Ogando A.

Cell Signal. 2007 Jul;19(7):1473-87. Epub 2007 Jan 25.

PMID:
17317102
19.

The extracellular linker of pro-neuregulin-alpha2c is required for efficient sorting and juxtacrine function.

Montero JC, Rodríguez-Barrueco R, Yuste L, Juanes PP, Borges J, Esparís-Ogando A, Pandiella A.

Mol Biol Cell. 2007 Feb;18(2):380-93. Epub 2006 Nov 15.

20.
21.

Overexpression of RasN17 fails to neutralize endogenous Ras in MCF7 breast cancer cells.

Yuste L, Esparís-Ogando A, Santos E, Pandiella A.

J Biochem. 2005 Jun;137(6):731-9.

PMID:
16002995
22.

Multifunctional role of Erk5 in multiple myeloma.

Carvajal-Vergara X, Tabera S, Montero JC, Esparís-Ogando A, López-Pérez R, Mateo G, Gutiérrez N, Parmo-Cabañas M, Teixidó J, San Miguel JF, Pandiella A.

Blood. 2005 Jun 1;105(11):4492-9. Epub 2005 Feb 3.

23.

Bortezomib is an efficient agent in plasma cell leukemias.

Esparís-Ogando A, Alegre A, Aguado B, Mateo G, Gutiérrez N, Bladé J, Schenkein D, Pandiella A, San Miguel JF.

Int J Cancer. 2005 Apr 20;114(4):665-7.

24.

Extracellular signal-regulated kinase phosphorylates tumor necrosis factor alpha-converting enzyme at threonine 735: a potential role in regulated shedding.

Díaz-Rodríguez E, Montero JC, Esparís-Ogando A, Yuste L, Pandiella A.

Mol Biol Cell. 2002 Jun;13(6):2031-44.

25.

Mitogen-activated protein kinase-dependent and -independent routes control shedding of transmembrane growth factors through multiple secretases.

Montero JC, Yuste L, Díaz-Rodríguez E, Esparís-Ogando A, Pandiella A.

Biochem J. 2002 Apr 15;363(Pt 2):211-21.

26.

Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2.

Esparís-Ogando A, Díaz-Rodríguez E, Montero JC, Yuste L, Crespo P, Pandiella A.

Mol Cell Biol. 2002 Jan;22(1):270-85.

27.

Differential shedding of transmembrane neuregulin isoforms by the tumor necrosis factor-alpha-converting enzyme.

Montero JC, Yuste L, Díaz-Rodríguez E, Esparís-Ogando A, Pandiella A.

Mol Cell Neurosci. 2000 Nov;16(5):631-48.

PMID:
11083924
28.

Stimulation of cleavage of membrane proteins by calmodulin inhibitors.

Díaz-Rodríguez E, Esparís-Ogando A, Montero JC, Yuste L, Pandiella A.

Biochem J. 2000 Mar 1;346 Pt 2:359-67.

29.
30.

Cleavage of the TrkA neurotrophin receptor by multiple metalloproteases generates signalling-competent truncated forms.

Díaz-Rodríguez E, Cabrera N, Esparís-Ogando A, Montero JC, Pandiella A.

Eur J Neurosci. 1999 Apr;11(4):1421-30.

PMID:
10103137
31.

Permeabilization of MDCK cells with cholesterol binding agents: dependence on substratum and confluency.

Esparís-Ogando A, Zurzolo C, Rodriguez-Boulan E.

Am J Physiol. 1994 Jul;267(1 Pt 1):C166-76.

PMID:
8048477
32.

The nicotinic receptors in the nervous system.

Gotti C, Sher E, Chini B, Fornasari D, Esparis Ogando A, Clementi F.

Pharmacol Res Commun. 1988 Aug;20(8):637-62. Review. No abstract available.

PMID:
3062640

Supplemental Content

Loading ...
Support Center